Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The relationship between serum aryl hydrocarbon receptor (AHR) agonistic activity levels with disease severity, its modulation over the course of relapsing-remitting MS (RRMS), and its regulation in progressive MS (PMS) are unknown. Here, we report the analysis of AHR agonistic activity levels in cross-sectional and longitudinal serum samples of patients with RRMS and PMS. METHODS: In a cross-sectional investigation, a total of 36 control patients diagnosed with noninflammatory diseases, 84 patients with RRMS, 35 patients with secondary progressive MS (SPMS), and 41 patients with primary progressive MS (PPMS) were included in this study. AHR activity was measured in a cell-based luciferase assay and correlated with age, sex, the presence of disease-modifying therapies, Expanded Disability Status Scale scores, and disease duration. In a second longitudinal investigation, we analyzed AHR activity in 13 patients diagnosed with RRMS over a period from 4 to 10 years and correlated AHR agonistic activity with white matter atrophy and lesion load volume changes. RESULTS: In RRMS, AHR ligand levels were globally decreased and associated with disease duration and neurologic disability. In SPMS and PPMS, serum AHR agonistic activity was decreased and correlated with disease severity. Finally, in longitudinal serum samples of patients with RRMS, decreased AHR agonistic activity was linked to progressive CNS atrophy and increased lesion load. CONCLUSIONS: These findings suggest that serum AHR agonist levels negatively correlate with disability in RRMS and PMS and decrease longitudinally in correlation with MRI markers of disease progression. Thus, serum AHR agonistic activity may serve as novel biomarker for disability progression in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 (2011) · Nature · doi:10.1038/nature10251 · Cited by 2,697
Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.003 · Cited by 2,614 · cited 2×
“Moreover, the essential amino acid tryptophan is broken down to several AHR ligands through multiple endogenous(37,38) and microbiome-dependent enzymatic pathways.(13) We and others have demonstrated the relevance of these dietary ligands in experimental models of CNS immunity, where their actions dampen proinflammato…”
BackgroundDenison, M. S., & Nagy, S. R. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135828 · Cited by 1,895 · cited 1×
“AHR agonists are provided by environmental, dietary, and endogenous sources.(2,11,12) Although xenobiotic ligands include pollutants and certain environmental toxins, the diet is a rich source of AHR ligands: cruciferous vegetables give rise to AHR ligands such as 3,39-diindolylmethane, indole-3-carbinol and indole-3-…”
BackgroundControl of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Self-citationRothhammer, V., Mascanfroni, I. D., Bunse, L., Takenaka, M. C., Kenison, J. E., Mayo, L., Chao, C.-C., Patel, B., Yan, R., Blain, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4106 · Cited by 1,559
Self-citationRothhammer, V., & Quintana, F. J. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0125-8 · Cited by 1,197 · cited 1×
“AHR agonists are provided by environmental, dietary, and endogenous sources.(2,11,12) Although xenobiotic ligands include pollutants and certain environmental toxins, the diet is a rich source of AHR ligands: cruciferous vegetables give rise to AHR ligands such as 3,39-diindolylmethane, indole-3-carbinol and indole-3-…”
BackgroundSelf-citationMicroglial control of astrocytes in response to microbial metabolites
Rothhammer, V., Borucki, D. M., Tjon, E. C., Takenaka, M. C., Chao, C.-C., Ardura-Fabregat, A., de Lima, K. A., Gutiérrez-Vázquez, C., Hewson, P., Staszewski, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0119-x · Cited by 1,051 · cited 6×
“Physiologically relevant AHR agonists are provided by environmental and dietary sources and also by the host metabolism(2,11,12) and commensal microbiota.(7,9,13) AHR activation has been reported to ameliorate preclinical models of MS(9,14) and reduced cerebral atrophy and lesion load in the human BRAVO and ALLEGRO cl…”
BackgroundMethodInfluentialSelf-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033 · cited 3×
“Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 2 | March 2021 3 activation in astrocytes and microglia limits diseasepromoting activities relevant to PMS pathogenesis.7,9,19 Thus, we analyzed serum AHR agonist levels in SPMS and PPMS to determine whether decreased AHR activation may…”
BackgroundLactobacillus reuteri induces gut intraepithelial CD4 + CD8αα + T cells
Cervantes-Barragan, L., Chai, J. N., Tianero, M. D., Di Luccia, B., Ahern, P. P., Merriman, J., Cortez, V. S., Caparon, M. G., Donia, M. S., Gilfillan, S., et al. (2017) · Science · doi:10.1126/science.aah5825 · Cited by 896
Neuronal vulnerability and multilineage diversity in multiple sclerosis
Schirmer, L., Velmeshev, D., Holmqvist, S., Kaufmann, M., Werneburg, S., Jung, D., Vistnes, S., Stockley, J. H., Young, A., Steindel, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1404-z · Cited by 638
Cited by
Regulation of microglial physiology by the microbiota
Cook, J., & Prinz, M. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2125739 · Cited by 49
“Thus, microbial tryptophan metabolism and AhR ligands are a promising lead for harnessing endogenous microglia-microbial signaling pathways in MS, and efforts to validate their role in human subjects are ongoing.(106)”
BackgroundAstrocytes and Microglia in Stress-Induced Neuroinflammation: The African Perspective
Olude, M. A., Mouihate, A., Mustapha, O. A., Farina, C., Quintana, F. J., & Olopade, J. O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795089 · Cited by 37
Self-citationAstrocyte-Derived Pleiotrophin Mitigates Late-Stage Autoimmune CNS Inflammation
Linnerbauer, M., Lößlein, L., Farrenkopf, D., Vandrey, O., Tsaktanis, T., Naumann, U., & Rothhammer, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800128 · Cited by 33
Self-citation
Metadata
- Authors
- Tsaktanis, T., Beyer, T., Nirschl, L., Linnerbauer, M., Grummel, V., Bussas, M., Tjon, E., Mühlau, M., Korn, T., Hemmer, B., Quintana, F. J., & Rothhammer, V.
- Venue
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2021-03-04
- Volume
- 8
- Issue
- 2
- ISSN
- 2332-7812 (ISSN-L)
- OpenAlex
- W3114855284
- Cited by
- 35
- References
- 15
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. https://app.cochat.ai/papers/10.1212/nxi.0000000000000933
- The paper
- Tsaktanis, T., Beyer, T., Nirschl, L., Linnerbauer, M., Grummel, V., Bussas, M., Tjon, E., Mühlau, M., Korn, T., Hemmer, B., Quintana, F. J., & Rothhammer, V. (2021). Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000000933
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.